WEDNESDAY, APRIL 5, 2017 ⢠6:00 PM â 10:00 PM
STATE OF THE SCIENCE SUMMIT: OVARIAN CANCER
WEDNESDAY, APRIL 5, 2017 • 6:00 PM – 10:00 PM LOCATION:
CHAIR:
The Phoenician 6000 E Camelback Rd Scottsdale, AZ 85251
Bradley J. Monk, MD, FACOF, FACS
Speakers: Heather Dalton, MD • Genetic Testing in Ovarian Cancer • Why test • Who to test • When to test • How to test (panel, germ-line, somatic) • How about HRD?
• PARP Inhibitors • Olaprib • Study 19 • Study 42 • SOLO-2 • SOLO-1 and -3 • Niraparib • Surgical Options in Newly Diagnosed Ovarian Cancer • NOVA and ATL • Neoadjuvant therapy • QUADRA • First-line Therapy Options • PRIMA • Chemo IV vs IP vs dose dense • Rucaparib • JGOG 3016 • “FDA data set” Kristeleit ESMO 2016 #8560 • GOG 262 • ARIEL 2 • MITO-7 • ARIEL 3 • GOG 172 • Immunotherapy • GOG 252 • Molecules under investigation and phase • iPOC 2 experience (Nivolimab, Pemprolizumab, • Addition of Bevacizumab Atezolizumab, Avelomab, Ipilimumab) • GOG 218 • NRG-GY003 • ICON 7 • JAVELIN 100 and 200 • ICON8b • NRG-GY009 and ATALANTE • Treatment of Recurrent Ovarian Cancer • Emerging Agents • Chemotherapy • Other investigational strategies • Impact of histology • Mirvetuximab soravtansine • Impact of PFI • CA4P • Impact of number of lines of therapy • Trabecedin • Impact of molecular signage • Farletuzamab • Chemo + bev • Combinations • AURELIA • Panel Case Discussions • OCEANS • Newly diagnosed ovarian cancer • GOG 213 (management through recurrence) • Platinum sensitive recurrent disease case • Third-line and beyond
Lyndsay J. Willmott, MD Dennis R. Scribner, Jr., MD, FACOG, FACS
To register, please contact Allison Cooper at: [email protected] or visit: www.onclive.com/meetings/soss
WEDNESDAY, APRIL 5, 2017 • 6:00 PM – 10:00 PM LOCATION:
CHAIR:
The Phoenician 6000 E Camelback Rd Scottsdale, AZ 85251
Bradley J. Monk, MD, FACOF, FACS
Speakers: Heather Dalton, MD • Genetic Testing in Ovarian Cancer • Why test • Who to test • When to test • How to test (panel, germ-line, somatic) • How about HRD?
• PARP Inhibitors • Olaprib • Study 19 • Study 42 • SOLO-2 • SOLO-1 and -3 • Niraparib • Surgical Options in Newly Diagnosed Ovarian Cancer • NOVA and ATL • Neoadjuvant therapy • QUADRA • First-line Therapy Options • PRIMA • Chemo IV vs IP vs dose dense • Rucaparib • JGOG 3016 • “FDA data set” Kristeleit ESMO 2016 #8560 • GOG 262 • ARIEL 2 • MITO-7 • ARIEL 3 • GOG 172 • Immunotherapy • GOG 252 • Molecules under investigation and phase • iPOC 2 experience (Nivolimab, Pemprolizumab, • Addition of Bevacizumab Atezolizumab, Avelomab, Ipilimumab) • GOG 218 • NRG-GY003 • ICON 7 • JAVELIN 100 and 200 • ICON8b • NRG-GY009 and ATALANTE • Treatment of Recurrent Ovarian Cancer • Emerging Agents • Chemotherapy • Other investigational strategies • Impact of histology • Mirvetuximab soravtansine • Impact of PFI • CA4P • Impact of number of lines of therapy • Trabecedin • Impact of molecular signage • Farletuzamab • Chemo + bev • Combinations • AURELIA • Panel Case Discussions • OCEANS • Newly diagnosed ovarian cancer • GOG 213 (management through recurrence) • Platinum sensitive recurrent disease case • Third-line and beyond
Lyndsay J. Willmott, MD Dennis R. Scribner, Jr., MD, FACOG, FACS
To register, please contact Allison Cooper at: [email protected] or visit: www.onclive.com/meetings/soss
